Abstract:In the past, little attention had been paid to the intestine and its microbial flora as a potential source of systemic inflammation in chronic kidney disease(CKD). Systemic inflammation plays a central role in progression of CKD and its cardiovascular and various other complications. The gastrointestinal tract houses a large community of microbes that have a symbiotic relationship with the host. The normal microbial flora protects the host against pathogenic microorganisms. It also contributes to the energy metabolism, micronutrient homeostasis and nitrogen bal- ance. Recent studies have revealed significant changes in the composition and function of the microbial flora in CKD patients and animals. These changes are driven by altered intestinal bio- chemical environment caused by: I-heavy influx of urea and uric acid from body fluids into the gastrointestinal tract, II- restrictions of potassium-rich food including fruits and vegetables which as the main source of indigestible complex carbohydrates are the essential nutrients for the guts' symbiotic microbial com- munity, and III- various medications such as phosphate binders, antibiotics etc. Together the changes in intestinal milieu and the resultant microbial dysbiosis play a major role in systemic inflammation and uremic toxicity by several mechanisms : I-generation of several microbial derived uremic toxins such as indoxyl sulfate, p-cresol sulfate and trimethylamine-N-oxide etc. II-reduction of microbial derived micronutrients such a short chain fatty acids (SCFA) which are the main source of nutrients for colonocytes. This is caused by diminished substrates (indigestible complex carbohydrates) which leads to depletion of SCFA-making bacteria. In addition, III-Disruption of the intestinal epithelial barrier by ammonia and ammonium hydroxide generated from hydrolysis of urea by urease-possessing microbial species which are common complications of CKD, and bowel ischemia caused by excessive use of diuretics (in CKD patients) and aggressive ultrafiltration by hemodialysis (in ESRD patients) can impair gastrointestinal epithelial barrier. The resulting breakdown of the gut epithelial barrier (tight junction complex) leads to influx of endotoxin, microbial fragments, and other noxious luminal products in the sub-epithelial tissue and systemic circulation leading to local and systemic inflammation and oxidative stress which are the major cause of morbidity and mortality in CKD population. This review is intended to provide an overview of the effects of CKD on the gut microbiome and intestinal epithelial barrier structure and the potential interventions aimed at mitigating these abnormalities.

Dysbiosis of Gut Microbiota Contributes to Uremic Cardiomyopathy via Induction of IFNγ-Producing CD4 <sup>+</sup> T Cells Expansion

Dysbiosis of Gut Microbiota Contributes to Uremic Cardiomyopathy via Induction of IFN-Producing CD4<SUP>+</SUP> T Cells Expansion

Dysbiosis of Gut Microbiota Contributes to Uremic Cardiomyopathy via Induction of IFNγ-Producing CD4+ T Cells Expansion

Dysbiosis of Gut Microbiota Contributes to Uremic Cardiomyopathy via the Induction of Th1 Cells Expansion

Gut Microbiota and Cardiovascular Uremic Toxicities

Roles of AhR/CYP1s Signal Pathway Mediated ROS Production in Uremic Cardiomyopathy

Roles of AhR/CYP1s signaling pathway mediated ROS production in uremic cardiomyopathy

Contribution of uremic dysbiosis to insulin resistance and sarcopenia

Is uremic cardiomyopathy a direct consequence of chronic kidney disease?

Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease.

Exploring the Microbiome in Heart Failure

[Uremic toxins and gut micro biome]

Uremic Toxins Are Conditional Danger‐ or Homeostasis‐ Associated Molecular Patterns, Which Are Highly Selective Increase Rather Than Purely Passive Accumulation, in Chronic Kidney Disease and Coronary Arteria Disease

Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in understanding pathophysiology

The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease

Cardiovascular Consequences of Uremic Metabolites: an Overview of the Involved Signaling Pathways

Gut-immune axis and cardiovascular risk in chronic kidney disease

Role of Uremic Toxins in Vascular Inflammation Associated with Chronic Kidney Disease

The Intestinal Microbiota and Metabolites in the Gut-Kidney-Heart Axis of Chronic Kidney Disease

Gut Bacterial Translocation Contributes to Microinflammation in Experimental Uremia